Moreover, NAD+ treatment inhibits the agonist-induced cardiac hypertrophy in vitro and in vivo through the Sirt3-LKB1-AMPK signaling pathway, suggesting that NAD+ supplementation is crucial for cardiac hypertrophy treatment [60]. The gene discussed is STK11; the disease is cardiac hypertrophy.